Filing Details
- Accession Number:
- 0001140361-15-023164
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-06-03 20:27:31
- Reporting Period:
- 2015-05-29
- Filing Date:
- 2015-06-03
- Accepted Time:
- 2015-06-03 20:27:31
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1048477 | Biomarin Pharmaceutical Inc | BMRN | Pharmaceutical Preparations (2834) | 680397820 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1238403 | K Daniel Spiegelman | C/O Biomarin Pharmaceutical Inc., 770 Lindaro St. San Rafael CA 94901 | Evp, Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2015-05-29 | 4,305 | $125.57 | 37,202 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2015-05-29 | 1,578 | $126.15 | 35,624 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-06-01 | 3,945 | $124.16 | 31,679 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- This transaction, which should have been reported on June 2, 2015, is being reported late due to an administrative oversight.
- Trade made pursuant to a 10b5-1 plan executed on March 11, 2015.
- The price in column 4 is a weighted average price. The price actually received ranged from $125.60 to $127.78. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- The price in column 4 is a weighted average price. The price actually received ranged from $123.06.60 to $124.93. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Billionaire Hedge Funds
